摘要
背景: 我们最近报道了表皮生长因子(EGF)通过激活p44/p42有丝分裂原激活蛋白(map)激酶、p38 map激酶、应激激活蛋白激酶/c-jun N末端激酶(SAPK/JNK)和Akt诱导成骨细胞样MC3T3-E1细胞的迁移。此外,我们证明热休克蛋白70(HSP70)通过抑制成骨细胞样MC3T3-E1细胞中p38- MAP激酶下调转化生长因子β刺激的血管内皮生长因子合成。然而,HSP70在成骨细胞迁移中的确切作用尚未完全阐明。 目的: 本研究旨在探讨热休克蛋白70抑制剂对表皮生长因子刺激的成骨细胞迁移的影响及其机制。 方法: 用两种类型的HSP70抑制剂(VER-155008或YM-08)治疗成骨细胞样MC3T3-E1细胞。对成骨细胞迁移进行了穿孔细胞迁移分析和伤口愈合分析。通过Western blot分析评价HSP70的表达水平和p38 MAP激酶、p44/p42 MAP激酶、SAPK/JNK或Akt的磷酸化。 结果: 在目前或不存在VER -155008的情况下,表皮生长因子几乎不影响hsp70的表达水平。通过跨井细胞迁移分析,HSP70抑制剂VER -155008和YM-08均能显著降低EGF刺激的迁移。通过伤口愈合实验,观察了两种热休克蛋白70抑制剂对表皮生长因子刺激的迁移的抑制作用。Ver-155008抑制了表皮生长因子诱导的p44/p42- MAP激酶和Akt的磷酸化,而不是p38- MAP激酶或SAPK/JNK。 结论: 这项研究提供了新的证据,证明HSP70抑制剂通过抑制p44/p42 MAP激酶和Akt减少了EGF刺激的成骨细胞迁移。
关键词: HSP70,EGF,迁移,p44/p42 MAP激酶,Akt,成骨细胞。
Current Molecular Medicine
Title:HSP70 Inhibitors Reduce The Osteoblast Migration By Epidermal Growth Factor
Volume: 18 Issue: 7
关键词: HSP70,EGF,迁移,p44/p42 MAP激酶,Akt,成骨细胞。
摘要: Background: We have recently reported that epidermal growth factor (EGF) induces migration of osteoblast-like MC3T3-E1 cells through the activation of p44/p42 mitogen-activated protein (MAP) kinase, p38 MAP kinase, stress-activated protein kinase/ c-Jun N-terminal kinase (SAPK/JNK) and Akt. Furthermore, we demonstrated that heat shock protein 70 (HSP70) down-regulates the transforming growth factor-β- stimulated vascular endothelial growth factor synthesis via suppression of p38 MAP kinase in osteoblast-like MC3T3-E1 cells. However, the exact role of HSP70 underlying osteoblast migration is not fully elucidated.
Objective: The aim of this study is to investigate the effects of HSP70 inhibitors on the EGF-stimulated osteoblast migration, and the underlying mechanism.
Methods: Osteoblast-like MC3T3-E1 cells were treated with two types of HSP70 inhibitors, VER-155008 or YM-08. Transwell cell migration assay and wound-healing assay were analyzed for osteoblast migration. The expression levels of HSP70 and the phosphorylation of p38 MAP kinase, p44/p42 MAP kinase, SAPK/JNK or Akt were evaluated by a Western blot analysis.
Results: EGF hardly affected the expression levels of HSP70 at the present or absent of VER-155008. EGF-stimulated migration was significantly reduced by both HSP70 inhibitors, VER-155008 and YM-08, determined by a transwell cell migration assay. The suppressive effects of both HSP70 inhibitors on the migration stimulated by EGF were also observed by a wound-healing assay. VER-155008 inhibited the EGF-induced phosphorylation of p44/p42 MAP kinase and AKT, but not p38 MAP kinase or SAPK/JNK.
Conclusion: This study provides new evidence that HSP70 inhibitors reduce the EGFstimulated migration of osteoblasts through the suppression of p44/p42 MAP kinase and Akt.
Export Options
About this article
Cite this article as:
HSP70 Inhibitors Reduce The Osteoblast Migration By Epidermal Growth Factor, Current Molecular Medicine 2018; 18 (7) . https://dx.doi.org/10.2174/1566524019666181213112847
DOI https://dx.doi.org/10.2174/1566524019666181213112847 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Imatinib Mesylate (Gleevec©): Targeted Therapy Against Cancer with Immune Properties
Endocrine, Metabolic & Immune Disorders - Drug Targets Fibroblast Growth Factor 2: From Laboratory Evidence to Clinical Application
Current Vascular Pharmacology From Multiple PAR1 Receptor/Protein Interactions to their Multiple Therapeutic Implications
Current Topics in Medicinal Chemistry Retracted: Tocotrienols and its Role in Cardiovascular Health- a Lead for Drug Design
Current Pharmaceutical Design Adverse Cardiovascular Effects of Antirheumatic Drugs: Implications for Clinical Practice and Research
Current Pharmaceutical Design Cerebrovascular Diseases in HIV-Infected Patients
Current HIV Research Is Bilirubin a Marker of Vascular Disease and/or Cancer and is it a Potential Therapeutic Target?
Current Pharmaceutical Design Acute <i>Versus</i> Chronic Administration of Calcineurin-Inhibitors Differentially Affect T-Cell Function
Endocrine, Metabolic & Immune Disorders - Drug Targets Therapeutic Apheresis in Metabolic Syndrome
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Cellular Senescence in Cardiovascular Diseases: Potential Age-Related Mechanisms and Implications for Treatment
Current Pharmaceutical Design The Potential Role of Pro-Inflammatory and Anti-Inflammatory Cytokines in Epilepsy Pathogenesis
Endocrine, Metabolic & Immune Disorders - Drug Targets Current and Emerging Therapeutic Approaches in HCV-Related Mixed Cryoglobulinemia
Current Medicinal Chemistry Oxidative Stress: Meeting Multiple Targets in Pathogenesis of Vascular Endothelial Dysfunction
Current Drug Targets Therapeutic Targets of Misguided T Cells in Systemic Lupus Erythematosus
Current Drug Targets - Inflammation & Allergy An Alternative “Trojan Horse” Hypothesis for COVID-19: Immune Deficiency of IL-10 and SARS-CoV-2 Biology
Endocrine, Metabolic & Immune Disorders - Drug Targets Mechanisms of Incretin Effects on Plasma Lipids and Implications for the Cardiovascular System
Cardiovascular & Hematological Agents in Medicinal Chemistry C-Reactive Protein and Asymmetric Dimethylarginine: Markers or Mediators in Cardiovascular Disorders?
Current Pharmaceutical Design Privileged Structures - Dream or Reality: Preferential Organization of Azanaphthalene Scaffold
Current Medicinal Chemistry TNF-Alpha Antagonism in Severe Asthma?
Recent Patents on Inflammation & Allergy Drug Discovery Prevalence of Anti-nuclear and Anti-phospholipid Antibodies in an Egyptian Cohort with Schizophrenia: A Case-control Study
Current Rheumatology Reviews